omniture
江苏康宁杰瑞生物制药有限公司

Latest News

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021

SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data ...

2021-06-07 10:11 5497

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021

* KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical...

2021-06-07 10:10 5274

Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021

* As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in th...

2021-06-07 09:53 4855

Poster to Highlight ENVASARC Pivotal Trial of Envafolimab (KN035) will be presented at the 2021 ASCO Annual Meeting

SUZHOU, China, May 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the s...

2021-05-24 08:54 4755

Alphamab Oncology to Present Multiple Clinical Research Data at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021)

SUZHOU, China, May 20, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, data...

2021-05-20 09:34 7782

Alphamab announced PD-L1/CTLA-4 bispecific antibody KN046 will enter new Phase II clinical trial in combination with Pfizer's Inlyta® (axitinib)

SUZHOU, China, April 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced that...

2021-04-29 08:00 3502

Alphamab Oncology Presented Clinical Data of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at AACR 2021

SUZHOU, China, April 13, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...

2021-04-13 08:15 2935

Alphamab Oncology Reports Full Year 2020 Financial Results and Business Highlights

SUZHOU, China, March 23, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), reported fin...

2021-03-23 23:08 3322

Alphamab Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.

SUZHOU, China, March 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2021-03-09 20:00 2467

Alphamab Oncology announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KN046 for the treatment of thymic epithelial tumor

SUZHOU, China, Sept. 3, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that...

2020-09-03 23:46 1601

Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody

SUZHOU, China, June 9, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that ...

2020-06-10 08:40 5207

Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer

SUZHOU, China, June 8, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) a clinical stag...

2020-06-09 10:10 5071

Alphamab Oncology, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China

SUZHOU, China, March 30, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced toda...

2020-03-30 19:00 2822

Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib)

SUZHOU, China, March 27, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced toda...

2020-03-27 19:00 3717

Alphamab Oncology Announces Completion of US$60 Million Series B Financing

SUZHOU, China, May 28, 2019 /PRNewswire/ -- Alphamab Oncology, a leading biopharmaceutical company ...

2019-05-28 19:02 2175

Alphamab Oncology is Invited to Present at the 37th Annual J.P. Morgan Healthcare Conference

SUZHOU, China, Jan. 4, 2019 /PRNewswire/ -- Alphamab Oncology, a clinical-stage biopharmaceutical c...

2019-01-04 17:02 1871

Alphamab Oncology Completes Series-A Round Financing - Further Strengthening Its Global Innovative Biologics Platforms

SUZHOU, China, Nov. 17, 2018 /PRNewswire/ -- Alphamab Oncology announced the successful completion ...

2018-11-17 00:12 2492

KN035, a Global Leading Subcutaneously-administered PD-L1 Antibody, Starts Late-stage Clinical Development

SUZHOU, China, Oct. 23, 2018 /PRNewswire/ -- Alphamab Oncology and 3D Medicines Inc. (3D Med) annou...

2018-10-23 19:03 2210

Alphamab Oncology's HER2 bispecific antibody KN026 gained US IND approval; phase I clinical trial started in China

SUZHOU, China, Oct. 16, 2018 /PRNewswire/ -- Alphamab Oncology announced that it has received US FD...

2018-10-16 18:18 1386

Alphamab Oncology's first-in-class PD-L1 - CTLA-4 bispecific antibody enters clinical trial

SUZHOU, China, Oct. 10, 2018 /PRNewswire/ -- Alphamab Oncology announced that its proprietary human...

2018-10-10 18:36 2022